

Date of preparation: 2022-05-28

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Extension of the scope of services under the manufacturing agreement with Novavax

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on the conclusion, with Novavax, Inc. ("Novavax"), of a commercial contract manufacturing agreement ("Manufacturing Agreement") and subsequent Current Reports regarding the expansion of cooperation with Novavax - No. 2/2022 of 14 January 2022 (order for production of cellular banks) and No. 3/2022 of 18 January 2022 (order for analytical services), the Management Board of Mabion S.A. ("Company") hereby informs that on 27 May 2022, in the night hours, the Company received an extension of the scope of services under the Manufacturing Agreement, signed by Novavax in the form of Statement of Work #4 ("SOW#4"). The extended scope of cooperation will include the quality test to be carried out by the Company, which is one of the most important analyses of the finished product. Therefore, the Company becomes an entity involved in the processes of release of finished products to the market.

The scope of SOW#4 includes, in the first instance, an assessment of feasibility to be carried out by the Company with regard to the analytical method ("feasibility" stage) and transferring, by the Company, the aforementioned method to the Company's quality system. The feasibility stage will be commenced immediately and will be completed as expected by both parties no later than the end of 2022. Then, during the term of the Manufacturing Agreement, i.e. in 2022-2025, under SOW#4, the Company will, on behalf of Novavax, perform sample analyses of the Novavax finished product (final product in the form of Nuvaxovid vaccine manufactured outside the Company) using the aforementioned GMP-compliant method, together with preparation of a certificate confirming the analysis performed.

The value of SOW#4 depends on the number of analytical tests performed by the Company in each year, with the maximum annual budget currently agreed at USD 1.8 million. In view of the Management Board, signing of SOW#4 is important for the Company primarily due to the next step in the process of expanding the cooperation with Novavax allowing the Company to further develop its Contract Development and Manufacturing Organization (CDMO) activities.